The Bits & Bytes Series - Robert Barrow
Hosted by Sia Sha
Robert Barrow is the CEO of MindMed, a psychedelic biotech company founded in 2019. MindMed was the first psychedelic company that was listed on the Nasdaq and is currently in clinical trials - for example, for exploring the efficacy of LSD on generalised anxiety disorder. 🧠📚 The company has a market cap of roughly 700m and has received investment from individuals such as Kevin O’Leary. 🏋️♀️
Rethink your brain health:
Timestamps:
1:35 - What are psychedelics?
2:45 - Why are psychedelics controversial? Is the controversy based on valid concerns?
7:25 - Has depression, anxiety, and disconnection been on the rise in recent years? Why is therapy not enough?
17:12 - Rob talks about his journey through MindMed, from a consultant to CEO, and the potential he saw in the company.
31:39 - Rob discuss development of psychedelics and how they plan to take it to market.
32:05 - Are there any adverse effects of the usage of psychedelics? How does MindMed test for them?
45:19 - How do psychedelics work on anxiety disorder?
1:00:00 - Rob discusses the end goal and vision of MindMed, and who he would like as colleagues in the company.
01:01:47 - Why did MindMed go public?
1:10:07 - Rob discuss planning for distribution channels
